Investment
Features
FeesSafety
Academy
More
Pluang+

Compare M&T Bank Corporation (MTB) vs Revvity Inc (RVTY) Price & Performance

M&T Bank CorporationTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

M&T Bank Corporation vs Revvity Inc — how do they compare? M&T Bank Corporation trades at $248.99 (market cap $36.15B), while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: M&T Bank Corporation is far larger — about 3× Revvity Inc's market cap, and M&T Bank Corporation pays the higher dividend (2.41%). Which is the better fit depends on your goals.

MTBRVTY
Market Cap
$36.15B$11.87B
Sector
FinancialsTechnology
52-Week High
$254.04$117.75
52-Week Low
$178.63$82.26
Dividend Yield
2.41%0.26%
Enterprise Value
$14.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

M&T Bank Corporation

M&T Bank (MTB) trades at $248.66, down 0.23% on the day, with a bullish technical outlook supported by moving averages and strong support near $248. The stock shows solid fundamentals, including a P/E of 13.2, net income margin of 30.85%, and three consecutive quarterly EPS beats, most recently with Q2 2026 actual EPS of $5.35 versus $4.66 expected. Revenue growth is steady, reaching $9.63 billion in 2025, and the company maintains a dividend, with H1-26 paying $1.50 per share.

The outlook for MTB is positive, driven by earnings momentum and analyst consensus, though risks include elevated debt levels and potential macroeconomic pressures on net interest income. With a consensus price target of $253.68 and 62.5% of analysts rating it Hold, the stock offers moderate upside with a focus on execution and loan growth sustainability.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About M&T Bank Corporation

M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.

Read more on MTB

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY